MindMed to Collaborate with Sphere Health to Enhance Mental Health Treatment
As
per the Centre for Disease Control and Prevention (CDC) report, people with
depressive disorder increased from 36.4% to 41.5% from August 2020 to February
2021, and adults between the age group of 18-29 are the most affected.
United States. A
leading biotech company, Mind Medicine, has planned to build a strategic
alliance with a mental health service provider, Sphere Health. The companies
have partnered to improve the understanding of various biomarkers related to
mental health illness. The plan is to jointly launch MM061302, a study
utilizing existing consumer technology to collect and analyze robust real-world
data for developing accurate machine learning tools. The advanced solutions
could help identify biomarkers and predict the symptoms of various mental
health problems, including anxiety and depression.
The
clinical study derived real-world data could help better understand various
factors behind mental health illnesses as well as support the designing of
digital tools for supporting individuals with mood disorders as well as
clinicians providing care.
Mind
Medicine (MindMed) is a psychedelic medicine biotech company that develops medicines
and therapies for people suffering from behavioral disorders and mental health
problems. The company has been building the most compelling drug pipeline in
psychedelics following novel-treatment paradigms to approach illnesses. Sphere
Health provides FDA-approved and modern mental health services to self-funded
employers.
Addressing
the partnership, MindMed’s Chief Medical Officer commented, “We are thrilled to
have Sphere Health as a partner in this endeavor. As the ways in which
individuals use technology to access care continues to evolve, so can our understanding
of mental illness and mental health. The use of technology has the potential to
offer a level of sensitivity and precision which does not currently exist in
our models of these disorders and, we hope, will ultimately lead to better
outcomes in our ability to help the folks who suffer from them.”
On the strategic partnership between two firms,
TechSci Research’s Director said, “With rapid surge in mental health disorders
and growing awareness towards them through education and advocacy, leading
players of global health market are creating alliances to develop new tools and
technologies for enhancing care. Besides, the key players are investing heavily
in research and development activities to develop innovative products to meet
the evolving demands of consumers.”
According
to TechSci Research report on “Global Psychobiotics Market By
Type (Food Supplements, Nutritional Supplements, Specialty Nutrients, Infant
Formula) By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus,
Clostridium, Others) By Form (Powder, Liquid/Fluid, Tablets) By Distribution
Channel (Retail Shops, Hypermarkets/Supermarkets, Drug Store/Pharmacy, Online)
By Application (Gastrointestinal Function, Antidepressant, Anxiolytic, Autism
Spectrum Disorder, Attention Deficit Hyperactivity Disorder, Schizophrenia,
Others) By Region, Competition Forecast & Opportunities, 2026”, the global
psychobiotics market is anticipated to grow at a formidable rate during the
forecast period. The growth can be attributed to the increasing demand of
probiotics for psychological ailments as well as rising incidences of anxiety
and depression. Besides, health woke population educated and informed about
psychobiotics and their easy availability are propelling the growth of global
psychobiotics market.